Companies /Healthcare

Johnson & Johnson

NYSE: JNJ Drug Manufacturers - General
$278.70
▼ $3.85 (−1.36%) today
Markets closed · 9:04am ET

24/7 Wall St. View

JNJ at a Glance

Valuation
Market cap
$670.9B
P/E ratio
42.3
Dividend yield
1.87%
Profitability
Revenue (TTM)
$99.3B
Profit margin
16.2%
EPS (TTM)
$6.59
Price
52-week range
$197 – $290
24/7 target
$303.84
Street target
$279.41
Earnings
Next report
Jan 26, 2027

Headquartered in New Brunswick, NJ Fiscal year ends December NYSE: JNJ jnj.com

About Johnson & Johnson

Johnson & Johnson is a global healthcare company operating through two business segments: Innovative Medicine and MedTech. The Innovative Medicine segment develops and commercializes therapies across oncology (DARZALEX, CARVYKTI, TECVAYLI, TALVEY, RYBREVANT/LAZCLUZE, ERLEADA, IMBRUVICA), immunology (TREMFYA, STELARA, SIMPONI/SIMPONI ARIA, REMICADE), neuroscience (SPRAVATO, CAPLYTA, INVEGA SUSTENNA/XEPLION/INVEGATRINZA/TREVICTA, CONCERTA), pulmonary hypertension (OPSUMIT/OPSYNVI, UPTRAVI), infectious diseases (EDURANT, PREZISTA/SYMTUZA), and cardiovascular/metabolism (XARELTO). The MedTech segment encompasses cardiovascular devices (electrophysiology products, Abiomed heart support, Shockwave intravascular lithotripsy), surgical instruments and solutions (advanced and general surgery), vision care (contact lenses and surgical ophthalmology), and orthopaedics (hips, knees, trauma, spine, and sports medicine). The company is in the process of planning a separation of its Orthopaedics business. Johnson & Johnson trades on the NYSE under the ticker JNJ and serves healthcare professionals and patients in markets worldwide. Updated

Latest Activity

FAA Ground Stop, Anthropic IPO and What to Expect From Nvidia and Nike Next Week

  • Nationwide FAA ground stop hit airlines after hours while cybersecurity names caught bids
  • Traders split on Anthropic's IPO: 17x sales versus SpaceX's 100x, with commoditization risk flagged
  • Peter Boockvar sees peak AI capex by 2027, rotating toward staples like Kimberly-Clark
  • Nike investor day preview with the stock at 13-year lows; desk picked Deere and J&J over Apple at 40x

The defensive rotation argument got concrete here: if AI capex peaks in 2027, the picks-and-shovels trade loses its bid first and staples absorb the flows. The desk's valuation game landed the same way, favoring Deere, Coca-Cola and Johnson & Johnson over richly priced tech, and few on the panel believe Nike's new CEO reverses share losses at next week's investor day.

TAKTakeda Pharmaceutical
52-week high
$21.44
+0.89%vs prior 52-week high · Nov 5, 2026

Takeda's $21.44 close tops the high it set on Nov. 5 by 0.89%, extending a steady climb in the large-cap drugmaker.

Related stockstoday
  • CORCencoraCustomer+2.8%
    Jun 17, 6:06 AM ET · SEC 10-K
  • CAHCardinal HealthCustomer+1.1%
    Mar 31, 2026 · SEC 10-K
  • JNJJohnson & JohnsonPartner+0.9%
    Jun 17, 6:06 AM ET · SEC 10-K

Moves: Nov 13, 2026 · Alpha Vantage daily close

8 more related stocks · 1 has no US listing

Nvidia Fallout, AI Financing Risk and Apple’s Safe-Haven Surge

  • Jensen Huang's exit leaves Nvidia down nearly a third from its $6 trillion peak, with the vendor-financing web in question
  • DA Davidson's Gil Lauria keeps a Buy but cuts his target to $200, preferring AMD, Broadcom and Micron near term
  • 10-year yields above 5.1% make neocloud financing costlier; NScale's S1 shows $5.5B of debt
  • Apple at 39x forward earnings framed as a Costco- or Walmart-style safe haven

Capital is rotating within the AI trade, moving from the Nvidia complex toward AMD and Micron, while Apple gets priced like a staple on 90% iPhone loyalty and almost no AI capex. The pressure point is funding costs, with debt-heavy neocloud borrowers the first to feel a higher 10-year yield.

Mad Money w/ Jim Cramer 11/11/26

  • Cramer says Nvidia leadership turmoil has made him gun shy on tech, yet writing off data center names risks big upside
  • CoreWeave CEO: compute demand 10 times oversubscribed for 2027, with chips recontracting at 20% to 50% premiums
  • Cramer would rather own Colgate or Johnson & Johnson than chase the noise right now
  • Caller questions on Darden's Olive Garden value proposition, Meta re-entry, and Jersey Mike's under Charlie Morrison

The tell is that four-year-old GPUs are being recontracted above their original prices, which undercuts the view that AI hardware depreciates into worthlessness. Cramer is keeping data center exposure in semis, networking, turbines and cooling even while trimming elsewhere, and he is leaning defensive with staples and pharma as the Nvidia story gets messier.

AI Rally Sets Emerging Stocks Up for Best Streak Since September

  • Bloomberg's Brody Ford: CoreWeave eased financing fears via customer prepayments and vendor financing, likely from Nvidia
  • Even after the jump, CoreWeave remains down more than 66% from its highs
  • Anthropic's IPO is already multiple times oversubscribed, with bankers weighing a $1.5 trillion valuation
  • J&J backed psychedelic-inspired biotech Delics with a $100 million oversubscribed round

The relief rally in CoreWeave rests on creative funding: prepayments and vendor financing bought time, and the stock is still more than 66% below its highs. Anthropic's oversubscribed IPO book at a $1.5 trillion valuation is the next read on how much AI spending the market will underwrite.

JNJJohnson & Johnson
52-week high
$282.11
+1.32%vs prior 52-week high · Sep 3, 2026

Johnson & Johnson closed at $282.11, clearing its September 3 peak by 1.32%. Gilead and AbbVie also finished higher.

Related stockstoday
  • GILDGilead SciencesPartner+1.5%
    Feb 24, 4:18 PM ET · SEC 10-K
  • ABBVAbbViePartner+0.7%
    Feb 11, 4:06 PM ET · SEC 10-K
  • TAKTakeda PharmaceuticalPartner+0.4%
    Jun 17, 6:06 AM ET · SEC 10-K

Moves: Nov 9, 2026 · Alpha Vantage daily close

4 more related stocks · 1 has no US listing

Mad Money w/ Jim Cramer 10/26/26

  • Cramer's bear case: a flood of IPOs and secondaries, $148B raised so far this year, drains the money that funds stocks
  • Applied Materials down from $739 to $387: buy 25 shares now, add on the pattern, finish in the 200s
  • Moderna after a parabolic move: let it come in before earnings, no buying parabolic charts
  • Thermo Fisher CEO on a beat-and-raise, BlackBerry's turnaround, and CrowdStrike cyber worries on deck

The call that matters for holders here is supply: Cramer argues the equity and debt markets are nearly tapped out after Meta, Alphabet and SpaceX raisings, with Anthropic's S1 now in line. He stops short of calling a top while pushing for buybacks and takeovers over further deals, favoring staged buying in Applied Materials and patience on Moderna.

Mad Money w/ Jim Cramer 10/13/26

  • Semis called the market's ball and chain: the VanEck chip ETF fell 7.22% over six sessions, its worst streak since May of last year
  • Cramer says Micron's China memory fears are overblown, pointing to 26 long-term take-or-pay contracts running to 2030
  • Apple stays a buy into the foldable two-screen iPhone, with new Siri devices driving memory and CPU demand
  • Wells Fargo should have been a winner on Charlie Scharf's rate-sensitive setup and next-year guidance

The call is to ignore the chip tape and look at where the silicon actually goes: Cramer argues Micron and AMD demand is real even as Korean memory pricing drags the whole group lower. He also thinks the bank selloff mispriced Wells Fargo, which makes more money if rates keep climbing.

JNJJohnson & Johnson
Regular session
$245.87
-3.38%open $254.46

A 3.4% slide to $245.87 is an outsized single day for a $592 billion defensive name, and it lands with earnings due today. The report arrives with the stock already repriced.

JNJJohnson & Johnson
Reports Tue Oct 13Before openConfirmed

Johnson & Johnson reports at 6:20 AM ET with consensus at $2.50 in EPS on $25.38 billion in revenue. The guidance commentary on talc settlement costs and device demand is what moves the stock.

    JNJ Coverage

    Frequently Asked Questions

    What does Johnson & Johnson do?

    Johnson & Johnson is a global healthcare company operating through two business segments: Innovative Medicine and MedTech.

    What is the JNJ stock price target?

    24/7 Wall St.'s 12-month price target for JNJ is $303.84, rated Buy. The Wall Street consensus target is $279.41. JNJ price prediction →